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Abstract
HIV-1 replicative capacity (RC) provides a measure of within-host fitness and is determined in the context of phenotypic
drug resistance testing. However it is unclear how these in-vitro measurements relate to in-vivo processes. Here we assess
RCs in a clinical setting by combining a previously published machine-learning tool, which predicts RC values from partial
pol sequences with genotypic and clinical data from the Swiss HIV Cohort Study. The machine-learning tool is based on a
training set consisting of 65000 RC measurements paired with their corresponding partial pol sequences. We find that
predicted RC values (pRCs) correlate significantly with the virus load measured in 2073 infected but drug naı¨ve individuals.
Furthermore, we find that, for 53 pairs of sequences, each pair sampled in the same infected individual, the pRC was
significantly higher for the sequence sampled later in the infection and that the increase in pRC was also significantly
correlated with the increase in plasma viral load and with the length of the time-interval between the sampling points.
These findings indicate that selection within a patient favors the evolution of higher replicative capacities and that these in-
vitro fitness measures are indicative of in-vivo HIV virus load.
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Introduction
Measuring the fitness of HIV-1 is notoriously difficult. At the
between-host level, fitness can be interpreted as the transmission
potential which is defined as the expected number of transmissions
in the course of an infection [1]. This quantity can however only
be measured in cohorts of untreated patients with known infection
status that are followed over long time periods [1]. At the within-
host level, fitness is determined by the average number of
secondary infected cells resulting from a single infected cell in
vivo. This hypothetical quantity is difficult to determine [2] but
can be approximated by in-vitro measurements of the replicative
capacity (RC) (see [3]). However, the in-vivo relevance of such in
vitro fitness values is largely unclear.
In a recent publication, some of the authors of this article
described a computational method to predict RC values on the
basis of viral amino-acid sequences [3]. To this end, a machine-
learning algorithm based on a quadratic fitness model was applied
to a training data set of 65,000 amino-acid sequences of the pol
gene and the associated RC values. The resulting RC-predictor
could explain roughly 40% of the deviance of RC values in a test-
data set consisting of 5,000 sequences, which had not been used
for the inference of this predictor. In the present study, we apply
this computational predictor to clinical data from the Swiss HIV
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Cohort Study (SHCS) (www.shcs.ch) in order to obtain an
assessment of the RC-predictor in an independent dataset and
to study its correlation with plasma HIV RNA viral load, a known
surrogate marker associated with disease progression [3].
Methods
Ethics statement
The Swiss HIV cohort study was approved by individual local
institutional review boards of all participating centers (www.shcs.
ch). Written informed consent was obtained for each SHCS study
participant.
RC-prediction
Fitness is measured as the log replicative capacity of HIV-
derived amplicons [representing all of Protease(PR) and most of
Reverse Transcriptase (RT)] inserted into a constant backbone of
a resistance test vector. The models are then trained to predict this
fitness from the amino-acid sequence of the amplicons. Details on
the experimental measurement of the RC values and on inferring
the predictor have been published in [3]. Here, we briefly reiterate
the principles of the models fitted.
In essence, the predictor is based on fitting the data consisting of
amino acid sequences s and the corresponding log-RC values (w)
with the following model
log (w(s))~Iz
X
ij
mijsijz
X
ijkl
eij;klsijskl ðM1Þ
sij denotes the presence (sij=1) or absence (sij=0) of allele j at
position i. (or more generally, if an ambiguity in the population
sequencing is consistent with several amino acids at a given position,
sij denotes the probability of allele j at position i). The model
parameters I, mij and eij;kl can be interpreted as intercept, main
effects, and epistatic effects. As the number of parameters exceeds
the number of data-points, the modelM1 has been fitted to the data
on the basis of a machine learning approach (generalized kernel
ridge regression). With this approach over-fitting is no concern
because the sub-dataset on which the predictor is evaluated is
independent from the sub-dataset from which the predictor is
inferred (see supplementary material of Hinkley et al. [3] for a
detailed description of the fitting procedure).
Clinical and sequence data
We assessed the RC-predictor by using two datasets collected
from untreated, chronically infected patients. The latter criterion
was introduced because HIV RNA levels are usually very high
during acute HIV infection, and it was ensured by discarding data
points measured within the first 180 days after the first positive
HIV test. The patients were enrolled in the Swiss HIV Cohort
Study, a longitudinal multicenter observational cohort study
(SHCS) (www.shcs.ch) [4]. These datasets consist of clinical data
(Table 1) and the corresponding viral amino acid sequences from
the SHCS drug resistance database [5]. We focus on patients, for
whom amino-acid sequences of the entire protease and the first
303 amino acids of the reverse transcriptase were available. We
only consider sequences, which have been obtained from therapy-
naı¨ve patients infected with HIV-1 subtype B because the training
set originated solely from subtype B strains. The first set consists of
nucleotide sequences with the corresponding HIV RNA virus load
measurements (plasma viral load set; n = 2073 patients). Selection
of viral load measurements is restricted to values obtained within
30 days before or after the genotypic tests, but before initiation of
antiretroviral therapy. The second set contains 53 patients for
whom genetic sequences are available at two time points, which
are at least 6 months apart (median [interquartile] distance
between the two measurements: 3.9 [1.9; 7.4] years; longitudinal
set) (see [6] for more details on this dataset).
Statistical analyses
Relationships between HIV RNA and pRC were modelled by
the use of univariable and multivariable linear regression. Model
assumptions were verified by inspecting residual versus fitted plots
and by checking for unequal variance across fitted values
(heteroskedasticity) and outliers. Because these diagnostics sug-
gested the presence of heteroskedasticity we performed ‘‘robust’’
versions of linear regressions, which estimate a weighted variance
based on the Huber2White method.
Statistical calculations were carried out with Stata 11.2 (Stata
Corp., College Station, TX, USA). The level of significance was
set at 0.05, and all p-values are two sided.
Results
Demographic and clinical characteristics of our study popula-
tion are displayed in table 1. We assessed the predicted RC (pRC)
with respect to two clinically relevant quantities or processes:
Firstly, the relation between pRC and virus-load measurements
measured around the same time and, secondly, the temporal
change of pRC within ART-naive individuals.
In the plasma viral load dataset (2073 patients), values for RC
predictions (pRC) were ranging from 21.07 to 1.43 units (median
[interquartile range] 0.62 [0.40; 0.81]), and corresponding median
[interquartile] HIV RNA levels were 4.7 log10 copies/mL [4.1;
5.2]. Using univariable linear regression analysis, we find a highly
significant effect of the pRC value on virus load (F2Test p,0.001;
see Figure 1A): a 1 unit increase in pRC is associated with an 0.57
increase [95% confidence interval 0.45; 0.69] in log10 HIV RNA.
The fraction of variance in virus load explained through the pRC
(R2) is 4.4%. Although somewhat attenuated, this effect of pRC on
virus load remains highly significant (p,0.001; 0.29 [0.18; 0.40]
log10 copies/mL HIV RNA per 1 unit increase in pRC ;table 1) if
we control in a multivariable regression model for age, ethnicity,
risk group, sex, CDC C stage and CD4 count at time of viral
sequencing, and the laboratory that generated the sequence data.
The association between HIV RNA and pRC changes only
minimally when the fully adjusted regression model is re-estimated
Author Summary
Determining how well different genotypes of HIV can
replicate within a patient is central for our understanding
of the evolution of HIV. Such in vivo fitness is often
approximated by in vitro measurements of viral replicative
capacities. Here we use a machine-learning algorithm to
predict in vitro replicative capacities from HIV nucleotide
sequences and compare these predicted replicative
capacities with clinical data from HIV-infected individuals.
We find that predicted replicative capacity correlates
significantly with the concentration of HIV RNA in the
plasma of infected individuals (virus load). Furthermore,
we show that the predicted replicative capacity increases
in the course of an infection. Finally, we found that the
temporal increase of replicative capacity correlates signif-
icantly with the temporal increase of virus load within a
patient. These results indicate that (predicted) replicative
capacity is a useful measure for viral fitness and suggest
that virus genetics determines virus load at least to some
extent via replicative capacity.
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on individuals without any evidence for transmitted drug
resistance mutations as defined by the most recent WHO
surveillance list [7] (n = 1909; regression coefficient [95%
confidence interval] 0.30 [0.18; 0.42] log10 copies HIV RNA
per unit change pRC).
For the longitudinal dataset, we find that the pRC value
increases in the course of an infection. Among the 53 patients with
two viral sequences available taken at least 6 months apart, the
median [interquartile] difference in pRC is 0.10 units [0.04; 0.25]
and is statistically significantly different from 0 (p sign
rank,0.001). Unadjusted linear regression estimates this increase
in pRC at 0.020 units per year [95% confidence interval 0.006;
0.035] (figure 1B). At the same time, HIV RNA also tended to be
higher at the second, later time point, with a median of 0.42 log10
copies/mL [20.28; 0.88] (sign rank p= 0.005). Consequently, we
find a statistically significant association between the change in
pRC correlates and the change in HIV RNA over time in these 53
patients when applying a linear regression model to the data,
which predicts a rise of 0.90 [0.01; 1.79] log10 copies/mL in HIV
RNA per 1 unit increase in pRC over time (figure 1C). This
finding suggests that within-host evolution seems to be character-
ized by a trend towards higher replication rates, and consequently
higher plasma HIV RNA viral loads.
The above analyses were based on untreated patients sampled
after the acute phase of the infection. We find similar results if we
exclude patients, which have been sampled in the AIDS phase
(defined as patients with at least one CDC stage C event, n = 206).
In particular, we still find a highly significant (p,0.001)
correlation between pRC and RNA load (slope: 1 unit increase
in pRC is associated with an 0.54 increase [95% confidence
interval 0.41; 0.66] in log10 HIV RNA) and a significant
(p = 0.0058) increase of RC over time (increase in pRC at 0.020
units per year [95% confidence interval 0.006; 0.035]). Only the
significance-level of the correlation between the temporal change
of pRC and the temporal change of RNA load changes from
‘significant’ (p = 0.04) to ‘trend’ (p = 0.058); however even in this
Table 1. Multivariable regression model to assess the association of log10 HIV RNA load with the predicted replicative capacity.
N (%)a
Regression Coefficient [95%
Confidence Interval] b P-value
Median [IQR] c estimated replicative capacity 0.62 [0.40 to 0.81] 0.29 [0.18 to 0.40] ,0.001
Sex 0.02
Male 1685 (82.3%) Reference
Female 388 (18.7%) 20.12 [20.22 to 20.02]
Median [IQR] age 37 [31 to 43] 0.02 [20.02 to 0.06] d 0.242
Mode of HIV acquisition ,0.001
Heterosexual contacts 483 (22.3%) 20.20 [20.29 to 20.11]
Homosexual contacts 1144 (55.2%) Reference
Intravenous drug use 446 (21.5%) 20.19 [20.28 to 20.10]
Ethnicity 0.015
White 1925 (92.9%) Reference
Black 24 (1.2%) 20.41 [20.66 to 20.16]
Hispanic 68 (3.3%) 20.10 [20.27 to 0.07]
Asian 35 (1.7%) 20.05 [20.22 to 0.12]
Other 21 (1.0%) 0.13 [20.18 to 0.43]
Sequence generating laboratory 0.087
A 215 (10.4%) Reference
B 420 (20.3%) 20.05 [20.19 to 0.09]
C 1438 (69.4%) 20.12 [20.24 to 0.01]
Median [IQR] year of sequence generation 2008 [2006 to 2008] 20.03 [20.05 to 20.01] e
Median [IQR] CD4 counts/microliter at time of sampling for
genotyping
298 [162 to 464] not donef
CD4 count groups (by 25th percentiles) f ,0.001
0 to 162 542 (25%) Reference
163 to 298 542 (25%) 20.41 [20.50 to 20.32]
299 to 464 543 (25%) 20.63 [20.72 to 20.53]
465 to 1522 541 (25%) 20.90 [21.00 to 20.79]
Ever had CDC stage C event prior to genotyping 206 (9.9%) 0.10 [20.01 to 0.21] 0.085
aunless stated otherwise.
bRegression coefficients printed in bold face are statistically significant at the 5% level.
cAbbreviations: IQR interquartile range.
dRegression coefficient per 10 years increase.
eRegression coefficient per year increase.
fbecause of better regression fit the final model included CD4 cell count as 4 categories.
doi:10.1371/journal.ppat.1002321.t001
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case the point estimates for the regression coefficient are very
similar in both cases (0.9[0.01; 1.79] vs. 0.84[20.03; 1.70]).
Discussion
How do the pRCs analyzed here relate to previous findings? For
example, the 6 sequences (in our data-set) carrying the lamivudine
mutation M184V, which has a large negative fitness effect on the
virus [8] and has been associated with an 0.3 log10 copies lower
HIV RNA relative to wild type [9], had a median [interquartile
range] pRC of 0.1 [21.3; 0.6], compared to 0.6 [0.4; 0.8] in the
1909 sequences without any transmitted resistance mutations
(Wilcoxon rank sum p,0.001). Overall, the pRC varied over a
range of 2.5 units from minimum to maximum. Our unadjusted
and adjusted regression models would therefore predict a
difference in HIV RNA of approximately 1.4 and 0.73 log10
copies/mL between the lowest and the highest pRC value. Yet
HIV RNA viral loads varied over 6 logs from 1.9 to 7.9 log10
copies/mL in our dataset. This discrepancy is not very surprising
given that our predictor for RC only takes the variation of 400
amino acid positions (roughly 10% of the genome of HIV) into
account. However, the finding of a correlation of pRC and HIV
RNA is robust, as confirmed by several sensitivity analyses, and it
is consistent with a number of previous studies, which have also
shown a correlation between in vitro measurements of RC and
virus load [10,11,12,13,14].
Our findings thus support the notion that virus load is to a large
extent controlled by virus genetics [15,16,17]. The fraction of
variance explained by pRC (4.4%) is much lower than the fraction
of variance in virus load explained by virus genetics in previous
studies [15,16,17], but it should be borne in mind that the
estimates of studies [15,16,17] are based on the variation in the
entire genome (Note that this is the case even for Alizon et al.[15],
because, even though the phylogenies used in that study were
inferred from the pol-gene, they reflect the relatedness of the entire
genome provided that recombination is not too common on an
epidemiological level). It should also be noted that our results
argue that at least a part of the virus’ genetic control of the virus
Figure 1. Clinical Relevance of predicted Replicative Capacity (pRC). (A) Relation between pRC and virus load (measured as log10(copies of
RNA/ml)) in the RNA-load dataset. (B) Temporal increase of pRC in the Longitudinal Dataset: relation between time difference between sequence
samples and the change in pRC. (C) Relation between change in pRC and change in RNA-load in the Longitudinal Dataset.
doi:10.1371/journal.ppat.1002321.g001
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load established in patients appears to be mediated by the
replicative capacity of the virus. This finding that virus load is
controlled by RC contrasts the interpretation that virus load is
mainly determined by the activation-rate of CD4 cells[18].
However, the relative importance of these different factors remains
an open question. The increase of pRCs over time is also
consistent with previous observations [19], and supports the view
that, within a single host, HIV is selected for higher replicative
capacities over time.
Overall our results show on the basis of a computational
predictor, firstly that in vitro replicative capacity increases in the
course of infection, which is consistent with the interpretation that
RC is a determinant of fitness at the within-host level, and
secondly that RC is linked to virus load, which has been shown to
be a in vivo determinant of viral fitness at an epidemiological level
[1]. In our view, it is remarkable that predicted RC based on
partial pol sequences representing only 10% of HIVs genome
correlates with virus load. Accordingly, taking into account the
variation in the entire HIV genome (as will become possible in the
future) may help to develop much more accurate predictors of
virus fitness and virus load.
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